The acquisition of Patch Biosciences by Ginkgo Bioworks is likely to be viewed positively by investors, as it enhances Ginkgo's technological capabilities and product offerings in the biotech space. The involvement of high-profile investors in Patch Biosciences, such as Andreessen Horowitz, could also add to the perceived value of this acquisition. However, without financial terms disclosed, the direct financial impact remains uncertain.